maltose mannitol sorbitol cyclodextrin silicic acid derivatives methyl cellulose carboxymethyl cellulose or salts thereof alginate gelatine polyvinylpyrrolidone calcium carbonate sodium hydrogencarbonate magnesium carbonate talc magnesium stearate gum arabic polyethylene glycol p hydroxybenzoic acid alkyl ester cetyl alcohol syrup ethanol propylene glycol vaseline carbowax glycerine sodium chloride sodium sulfite sodium phosphate citric acid lactic acid polylactic acid and polylactic acid glycolic acid can be named while the content of tzt 1027 or a salt s thereof in such preparations is variable depending on individual preparation forms it is generally desirable to use tzt 1027 or salt s thereof at a concentration level within a range of 0 1 u2013 50 wt for solid and semi solid preparation forms and at a concentration level within a range of 0 05 u2013 10 wt for liquid preparation forms according to the present invention where crystals of tzt 1027 or salt s thereof are used as the active ingredient of anti tumor agents it is particularly preferred to use them as formulated into injections or orally administerable preparations hereinafter the present invention is more specifically explained referring to working examples in the following examples melting points were measured with yamato melting point apparatus mp 21 model infrared absorption spectra were measured by the paste method according to japanese pharmacopeia general test method with perkin elmer ft ir spectrometer 1600 series ultraviolet absorption spectra were measured with hitachi u 3210 spectrophotometer as to 0 01 mol l hydrochloric acid ethanol 95 solution of tzt 1027 by the absorptiometric method according to japanese.